E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Antibody mediated rejection after kidney transplant |
Rechazo mediado por anticuerpos tras trasplante de riñón |
|
E.1.1.1 | Medical condition in easily understood language |
Kidney transplant rejection |
Rechazo trasplante de riñón |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Immune system processes [G12] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10064683 |
E.1.2 | Term | Antibody-mediated rejection |
E.1.2 | System Organ Class | 10021428 - Immune system disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and potential efficacy of eculizumab to prevent AMR in sensitized recipients of deceased donor kidney transplants. |
Evaluar la seguridad y potencial eficacia de eculizumab en la prevención del rechazo mediado por anticuerpos (RMA) en receptores sensibilizados de trasplante de riñón de donante fallecido |
|
E.2.2 | Secondary objectives of the trial |
Safety and efficacy |
Seguridad y eficacia |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female patients ? 18 years old 2. Patients with Stage V chronic kidney disease who will receive a kidney transplant from a deceased donor to whom they are sensitized 3. Patients must be able to understand the informed consent form and willing to comply with study procedures |
1. Pacientes, hombres o mujeres, ? 18 años 2. Pacientes con enfermedad renal crónica en estadio V que recibirán un trasplante de riñón de un donante fallecido para el que son sensibles 3. Los pacientes deben ser capces de entender el consentimiento informado y estar dispuestos a cumplir con los procedimientos del estudio. |
|
E.4 | Principal exclusion criteria |
1. Has received treatment with eculizumab at any time prior to enrolling in this study 2. ABO incompatible with deceased donor |
1. Haber recibido tratamiento con eculizumab en cualquier momento antes de su inclusión en este estudio 2. ABO incompatible con el donante fallecido |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To evaluate the safety and potential efficacy of eculizumab to prevent AMR in sensitized recipients of deceased donor kidney transplants. |
Evaluar la seguridad y potencial eficacia de eculizumab en la prevención del rechazo mediado por anticuerpos (RMA) en receptores sensibilizados de trasplante de riñón de donante fallecido |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Cumulative incidence of AMR between Week 9 and Month 12 post-transplantation |
Incidencia acumulada del Rechazo mediado por anticuerpos (RMA) que se produce entre la semana 9 y el mes 12 tras el trasplante |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last patient |
Ultima visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |